These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 27935577)

  • 1. Bone marrow fibrosis grade is an independent risk factor for overall survival in patients with primary myelofibrosis.
    Li B; Zhang P; Feng G; Xu Z; Qin T; Zhang Y; Sha Z; Dong D; Zhang H; Fang L; Pan L; Hu N; Qu S; Cai W; Huang G; Xiao Z
    Blood Cancer J; 2016 Dec; 6(12):e505. PubMed ID: 27935577
    [No Abstract]   [Full Text] [Related]  

  • 2. Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome.
    Asp J; Andréasson B; Hansson U; Wasslavik C; Abelsson J; Johansson P; Palmqvist L
    Haematologica; 2016 Apr; 101(4):e129-32. PubMed ID: 26768689
    [No Abstract]   [Full Text] [Related]  

  • 3. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
    Rozovski U; Verstovsek S; Manshouri T; Dembitz V; Bozinovic K; Newberry K; Zhang Y; Bove JE; Pierce S; Kantarjian H; Estrov Z
    Haematologica; 2017 Jan; 102(1):79-84. PubMed ID: 27686378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach.
    Iurlo A; Elli EM; Palandri F; Cattaneo D; Bossi A; Cortinovis I; Bucelli C; Orofino N; Brioschi F; Auteri G; Bianchi P; Fabris S; Isimbaldi G; Sabattini E; Baldini L; Gianelli U
    Hematol Oncol; 2019 Oct; 37(4):424-433. PubMed ID: 31359447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.
    Rumi E; Cazzola M
    Blood; 2017 Feb; 129(6):680-692. PubMed ID: 28028026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis.
    Pardanani A; Abdelrahman RA; Finke C; Lasho TT; Begna KH; Al-Kali A; Hogan WJ; Litzow MR; Hanson CA; Ketterling RP; Tefferi A
    Leukemia; 2015 Mar; 29(3):741-4. PubMed ID: 25322686
    [No Abstract]   [Full Text] [Related]  

  • 7. CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis.
    Finazzi MC; Carobbio A; Cervantes F; Isola IM; Vannucchi AM; Guglielmelli P; Rambaldi A; Finazzi G; Barosi G; Barbui T
    Leukemia; 2015 May; 29(5):1209-10. PubMed ID: 25482134
    [No Abstract]   [Full Text] [Related]  

  • 8. Co-occurrence of type I CALR and two MPL mutations in patient with primary myelofibrosis.
    Tashkandi H; Moore EM; Tomlinson B; Goebel T; Sadri N
    Ann Hematol; 2017 Aug; 96(8):1417-1418. PubMed ID: 28502030
    [No Abstract]   [Full Text] [Related]  

  • 9. Driver mutation-specific clinical and genomic correlates differ between primary and secondary myelofibrosis.
    Kuykendall AT; Talati C; Padron E; Sweet K; Lancet JE; List AF; Sallman D; Komrokji RS
    Am J Hematol; 2019 Dec; 94(12):E314-E317. PubMed ID: 31444809
    [No Abstract]   [Full Text] [Related]  

  • 10. The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly-annotated patients with primary myelofibrosis.
    Tefferi A; Lasho TL; Mudireddy M; Finke CM; Hanson CA; Ketterling RP; Gangat N; Pardanani A
    Am J Hematol; 2019 Mar; 94(3):299-305. PubMed ID: 30516848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis.
    Palandri F; Latagliata R; Polverelli N; Tieghi A; Crugnola M; Martino B; Perricone M; Breccia M; Ottaviani E; Testoni N; Merli F; Aversa F; Alimena G; Cavo M; Martinelli G; Catani L; Baccarani M; Vianelli N
    Leukemia; 2015 Jun; 29(6):1344-9. PubMed ID: 25801912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Important Pathologic Considerations for Establishing the Diagnosis of Myelofibrosis.
    Salama ME
    Hematol Oncol Clin North Am; 2021 Apr; 35(2):267-278. PubMed ID: 33641868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Searching for CALRity in myeloproliferative neoplasms.
    Cook JR
    Am J Clin Pathol; 2015 May; 143(5):617-9. PubMed ID: 25873492
    [No Abstract]   [Full Text] [Related]  

  • 15. Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact.
    Tefferi A; Lasho TL; Finke C; Belachew AA; Wassie EA; Ketterling RP; Hanson CA; Pardanani A
    Leukemia; 2014 Jul; 28(7):1568-70. PubMed ID: 24569778
    [No Abstract]   [Full Text] [Related]  

  • 16. Somatic mutations of calreticulin in myeloproliferative neoplasms.
    Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
    N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoimmune Myelofibrosis: Clinical Features, Course, and Outcome.
    Piatek CI; Vergara-Lluri ME; Pullarkat V; Siddiqi IN; O'Connell C; Brynes RK; Feinstein DI
    Acta Haematol; 2017; 138(3):129-137. PubMed ID: 28866671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of molecular residual disease post allografting in myelofibrosis patients.
    Wolschke C; Badbaran A; Zabelina T; Christopeit M; Ayuk F; Triviai I; Zander A; Alchalby H; Bacher U; Fehse B; Kröger N
    Bone Marrow Transplant; 2017 Nov; 52(11):1526-1529. PubMed ID: 28714945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capricious CALR mutated clones in myeloproliferative neoplasms.
    Haslam K; Conneally E; Langabeer SE
    Blood Cells Mol Dis; 2016 Mar; 57():110-1. PubMed ID: 26777583
    [No Abstract]   [Full Text] [Related]  

  • 20. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.
    Al Assaf C; Van Obbergh F; Billiet J; Lierman E; Devos T; Graux C; Hervent AS; Emmerechts J; Tousseyn T; De Paepe P; Papadopoulos P; Michaux L; Vandenberghe P
    Haematologica; 2015 Jul; 100(7):893-7. PubMed ID: 25934766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.